Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,886.80
    -1,173.40 (-1.33%)
     

  • CMC Crypto 200

    1,329.64
    -66.90 (-4.79%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARIA, GALE, IMMU and VNDA

ACCESSWIRE

The Biotech Industry has provided investors with impressive gains over the past year. The NASDAQ Biotech Index (NASDAQ:NBI) and the SPDR S&P Biotech ETF (NYSE:XBI - News) have seen gains of approximately 46 percent and 37 percent, respectively, in the past year. Over the same period the NASDAQ and S&P 500 Index have posted gains of 23 percent and 25.5, respectively. The U.S. Food and Drug Administration approved a total of 39 new drugs in 2012, the second highest total since 1996.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA - News) shares traded in the range of $18.94 to $19.51 Thursday before settling to close at $18.96. The stock appears to be facing resistance at $19.60 with strong support at $18.76. The company is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5th. Ariad Pharmaceuticals shares have gained approximately 13 percent in the past year.

More information on Ariad Pharmaceuticalsand access to the free equity report can be found at: www.WallStreetFundamentals.com/ARIA

Galena Biopharma Inc. (NASDAQ:GALE - News) shares traded in the range of $2.43 to $2.50 Thursday before settling to close at $2.44. The stock appears to be facing stiff resistance at $2.50. Galena’s NeuVax is the first adjuvant breast cancer vaccine to enter pivotal Phase 3 clinical trials. Shares of Galena Biopharma have gained approximately 86 percent in the past year.

ADVERTISEMENT

More information on Galena Biopharma and access to the free equity report can be found at: www.WallStreetFundamentals.com/GALE

Immunomedics, Inc. (NASDAQ:IMMU - News) shares traded in the range of $3.46 to $3.99 Thursday before
settling to close at $3.92. The stock appears to be facing some support at the $2.24 and $2.31 levels. The company recently provided an update on the progress of the antibody-drug conjugate (ADC) programs at the New York Biotechnology Association's Annual Meeting.Immunomedics shares have gained approximately 16 percent in the past year.

More information onImmunomedicsand access to the free equity report can be found at: www.WallStreetFundamentals.com/IMMU

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - News) shares traded in the range of $8.36 to
$9.48 Thursday before settling to close at $9.20. The stock appears to have some support at $8.32. The company plans to submit a New Drug Application fortasimelteon for Non-24-Hour Disorder sometime in mid-2013. Shares of Vanda Pharmaceuticals have gained approximately 95 percent in the past year.

More information onVanda Pharmaceuticalsand access to the free equity report can be found at: www.WallStreetFundamentals.com/VNDA

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer:
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact: Wall Street Fundamentals Website: www.WallStreetFundamentals.com Email: editor@wallstreetfundamentals.com